Infliximab Monoclonal Antibody from Canada
Infliximab (Remicade) is a chimeric monoclonal antibody neutralizing TNF-alpha for Crohn's disease and psoriasis. Classifies in HTS 3002.13.0010 for unmixed monoclonal immunological products from biotech, aligning with chapter's peptide/protein definition. Bulk for further processing.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Document GMP compliance from EU or other certified facilities for faster release
• Test for immunogenicity profiles in COA to support therapeutic claims
• Avoid bulk packaging resembling retail to prevent 3002.15 reclassification